Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 6/20 | 0.63 |
| ▸ | PRKAG1 | P54619 | 6/20 | 0.63 |
| ▸ | PRKAA2 | P54646 | 6/20 | 0.63 |
| ▸ | PRKAA1 | Q13131 | 6/20 | 0.63 |
| ▸ | PRKAG3 | Q9UGI9 | 6/20 | 0.63 |
| ▸ | PRKAG2 | Q9UGJ0 | 6/20 | 0.63 |
| ▸ | PRKAB1 | Q9Y478 | 6/20 | 0.63 |
| ▸ | F7 | P08709 | 1/20 | 0.57 |
| ▸ | F3 | P13726 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.47 |
| ▸ | NHERF1 | O14745 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2056326 | 0.82 | GABRA1 (0.63) | F7F3GABRA1GABRB2 | |
| SCHEMBL15901066 | 0.81 | HAT1 (0.47) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL6648434 | 0.81 | GABRA1 (0.46) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL15902428 | 0.80 | HAT1 (0.52) | — | |
| SCHEMBL30934603 | 0.79 | F7 (0.55) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL25253727 | 0.79 | F7 (0.55) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL25215041 | 0.79 | STING1 (0.43) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL6139981 | 0.78 | GABRA1 (0.50) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL15300878 | 0.78 | PRKAB2 (1.00) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL3812183 | 0.77 | HTT (0.52) | KDM4EGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| WO-2021138434-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | PRKAB2 158/4885PRKAG1 57/4885PRKAA2 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.